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The mechanistic underpinnings of metastatic dor-
mancy and reactivation are poorly understood. A
gain-of-function cDNA screen reveals that Coco,
a secreted antagonist of TGF-b ligands, induces
dormant breast cancer cells to undergo reactivation
in the lung. Mechanistic studies indicate that Coco
exerts this effect by blocking lung-derived BMP
ligands. Whereas Coco enhances the manifestation
of traits associated with cancer stem cells, BMP
signaling suppresses it. Coco induces a discrete
gene expression signature, which is strongly associ-
ated with metastatic relapse to the lung, but not to
the bone or brain in patients. Experiments in mouse
models suggest that these latter organs contain
niches devoid of bioactive BMP. These findings
reveal that metastasis-initiating cells need to over-
come organ-specific antimetastatic signals in order
to undergo reactivation.INTRODUCTION
Metastatic relapse of breast cancer and other carcinomas
frequently occurs several years after initial surgery. Increasing
evidence suggests that tumor cells that have disseminated
from early lesions, including ductal carcinomas in situ, undergo
an extended period of dormancy in the stroma of target organs
(Nguyen et al., 2009; Valastyan and Weinberg, 2011). It is
currently unclear if tumor cells become dormant as a con-
sequence of intrinsic defects or in response to inhibitory signals
that they encounter in foreign microenvironments.
Many malignancies, including breast cancer, are fueled by a
limited, although not necessarily small, number of cancer stem
cells, which undergo self-renewal as well as generate rapidly
proliferating progenitors and aberrantly differentiated postmi-764 Cell 150, 764–779, August 17, 2012 ª2012 Elsevier Inc.totic cells (Clevers, 2011; Gupta et al., 2009). The metastatic
capacity of human pancreatic and colorectal cancers is re-
stricted to a subpopulation that includes cancer stem cells
(Hermann et al., 2007; Pang et al., 2010). Furthermore, the
epithelial to mesenchymal transition (EMT) that facilitates tumor
dissemination produces cells endowed with the capacity to self-
renew, suggesting that these two cellular processes are inti-
mately linked (Mani et al., 2008). Finally, the Id1/3 transcription
factors and the miR200 and miR335 microRNAs promote the
colonization phase of breast cancer metastasis at least in part
by modulating cancer stem cell function (Gupta et al., 2007;
Korpal et al., 2011; Shimono et al., 2009; Tavazoie et al., 2008).
These results suggest that the cancer stem cells possess the
migratory and self-renewal capabilities necessary to colonize
distant organs, whereas the remaining tumor cells lack meta-
static capacity.
The ability of metastasis-initiating cells to enter into, and
eventually exit from, proliferative quiescence suggests an addi-
tional commonality with adult tissue stem cells. However, the
relationship between cancer stem cell behavior and dormancy
atmetastatic sites is poorly understood. In this study, we provide
evidence that Coco, a secreted antagonist of TGF-b ligands,
induces dormant metastasis-initiating cells to undergo reactiva-
tion in the lung. Mechanistic studies suggest that Coco exerts
this function by blocking paracrine BMP signaling and thereby
enhancing the self-renewal capability of metastasis-initiating
cells.
RESULTS
A Gain-of-Function Screen for Genes that Mediate
the Postdissemination Phase of Metastasis
We designed a gain-of-function cDNA screen that uses the
mouse as a filter to isolate genes that mediate metastasis (Fig-
ure 1A) and applied it to a previously described series of
mammary carcinoma cell lines, which appear to be arrested at
defined steps of metastasis (Aslakson and Miller, 1992). Upon
orthotopic injection, the 67NR cells give rise to noninvasive
ATG
AAAAA
cDNA library
in viral vector
Poorly metastatic
target cells
Metastatic cells
Mammary fat pad
injection
Recovery of cells from
lung metastases
Rescue of integrated provirus
and cDNA sequencing
67NR    168FARN     4TO7         4T1
+           +           +           +
-            +          +/-         +/-
-            -           +            +
-            -           +            +
-            -            -            +
8 cDNAs
(3 validated)
No
cDNANo
cDNA
Primary tumor
growth
Lymphnode
colonization
Intravasation
Lung homing
Metastasis
A B
Validation
(reinjection of cells
transduced with the cDNA) 
Medium
Cell layer
Coco
Coco
β-actin
67
NR
   1
68
FA
RN
    
   4
TO
7
    
    
  4
T1
Coco
β-actin
-   +    -   +    -   +    -    +    Trypsin
C
el
l l
ay
er
4T
O
7-
TG
L
Myc
β-actin
Ve
cto
r
    
Co
co
Ve
ct
or
C
oc
o
30 min    3 weeks  4 weeks  5 weeks
0       1       2       3       4       5
Weeks
N
or
m
al
iz
ed
 p
ho
to
n 
flu
x
102
10
1
0.1
103
Vector (n=10)
Coco (n=10)
67
NR
16
8F
AR
N
4T
O7 4T
1
4T
1-
TG
L
Coco
β-actin
sh
-C
on
tro
l
    
sh
 #1
    
   s
h #
3
sh
-C
oc
o 
#3
sh
-C
oc
o 
#1
sh
-C
on
tr
ol
30 min  3 weeks  4 weeks  5 weeks
102
10
1
103
104
0       1       2       3       4       5
Weeks
sh-Control (n=10)
sh-Coco #1 (n=10)
sh-Coco #3 (n=10)
N
or
m
al
iz
ed
 p
ho
to
n 
flu
x
0
100
200
300
400
500
4TO7-Vector (n=10)
4TO7-Coco (n=10)
2         3        4         5        6         7       
Weeks
Tu
m
or
 v
ol
um
e 
(m
m
3 )
Primary tumor growth
4T1-TGL
4TO7-TGL
P=1.1E-4
P<6.5E-4
2 x 105 cells
P>0.05
C
D E
G
H
0
100
200
300
400
500
600
700
800
900
2         3         4         5        6         7
sh-Control (n=30)
sh-Coco #1 (n=30)
sh-Coco #3 (n=30)
1 x 105 cells
P>0.05
Weeks
Primary tumor growth
Tu
m
or
 v
ol
um
e 
(m
m
3 )
F
Figure 1. Coco Mediates Lung Colonization
(A) Gain-of-function retroviral cDNA screen.
(B) Metastatic capabilities of the cell lines and results of the first screen.
(C) Proteins precipitated from supernatants (4 ml) or extracted from cell layers (30 mg) were subjected to immunoblotting (top). Cells were treated with or without
trypsin for 30 min before immunoblotting (bottom).
(D) 4TO7-TGL cells transduced with myc-Coco or empty vector (top) and 4T1 cells expressing a control shRNA (sh-Control) or 2 shRNAs targeting Coco
(sh #1 and #3) were subjected to immunoblotting.
(E and F) 4TO7-TGL cells expressing Coco or not (E) and control and Coco-silenced 4T1-TGL cells (F) were inoculated orthotopically in syngeneic mice. The
graphs show mean tumor volumes.
(G and H) 4TO7-TGL cells expressing Coco or not (G) and control and Coco-silenced 4T1-TGL cells (H) were inoculated intravenously (i.v.). Lung metastasis was
measured by bioluminescent imaging. The panels show representative images (left) and the graph shows the normalized photon flux (right).
In all panels, error bars represent SD. See also Figure S1.
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Figure 2. Coco Induces Reactivation in the Lung
(A) Mice were injected i.v. with 4TO7-TGL cells expressing Coco or not and sacrificed at the indicated times. Lung sections were stained as indicated.
(B) The graph shows the number of GFP-positive solitary tumor cells per microscopic field (left vertical axis) and of metastatic lesions per lung section (right
vertical axis) at the indicated times. Metastases were detected only in the lungs of mice injected with 4TO7-Coco cells (red bars; p < 5.6 3 104 at 21 days and
p < 3.1 3 105 at 35 days).
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tumors, the 168FARN cells colonize locoregional lymphnodes
but do not gain access to the vasculature, and the 4TO7
cells are able to disseminate but do not produce macroscopic
metastases (macrometastases). In contrast, the 4T1 cells pro-
duce macrometastases in the lung (Figure 1B). Upon transduc-
tion with cDNA libraries derived from 4T1 cells, the 67NR or
168FARN cells did not acquire the capability to give rise to
lung metastases in 8 weeks, suggesting that the introduction
of a single gene did not enable these cells to penetrate into the
bloodstream and acquire the additional capabilities required
for metastatic colonization. In contrast, the 4TO7 cells infected
with the 4T1 libraries produced a total of eight lung nodules in
multiple mice (Figure 1B). After proviral rescue and reintroduc-
tion in 4TO7 cells, three of the eight cDNAs isolated from indi-
vidual lesions promoted lung metastasis without affecting
primary tumor growth (Figure S1A available online; data not
shown). In contrast, 4TO7 cells infected with empty vector did
not produce macroscopic lesions upon injection in 30 mice.
This screening strategy can thus be used to identify mediators
of the homing and outgrowth step of metastasis.
Coco Promotes Lung Colonization
We focused on cDNA1 because it encoded an N-terminally trun-
cated but potentially active version of Coco, a secreted inhibitor
of TGF-b ligands (Bell et al., 2003) (Figure S1B). Rossant and
colleagues had isolated the same transcript and termed it Dante
(Pearce et al., 1999). Studies on frog development had shown
that Coco binds directly to BMP and Nodal proteins, blocking
their ability to bind to their cognate receptors, and interferes
with Wnt signaling (Bell et al., 2003). Experiments in Xenopus
embryos and 4TO7 cells indicated that cDNA1 possesses all
the biological activities of full-length Coco (Figures S1C–S1F).
Conversely, expression of full-length Coco induced the 4TO7
cells to colonize the lung after orthotopic injection, confirming
that Coco promotes spontaneous metastasis similar to cDNA1
(Figure S1G).
The expression of Coco correlated with metastatic capability
in the 4T1 progression series (Figure 1C, top). Of note, a large
fraction of Coco remained associated with the cell layer rather
than diffusing in the medium (Figure 1C, top). Treatment of live
cells with modest amounts of highly purified trypsin led to the
disappearance of Coco from the cell layer (Figure 1C, bottom),
indicating that this inhibitor associates with the pericellular(C) Outline of the EdU incorporation experiment.
(D) Representative images of lung sections stained as indicated.
(E) The graph shows the percentage of EdU+ cells at the indicated times. Cells e
(F) Control (sh-Control) and Coco-silenced (sh-Coco #1 and #3) 4T1-TGL cells we
graph shows the percentage of Ki-67+ tumor cells at the indicated times. Contro
(G) Semiquantitative RT-PCR analysis of BMP receptors (top). Cells were left untre
(bottom).
(H and I) 4TO7 and 4TO7-Coco cells were inoculated i.v. and lung sections were s
percentage of P-Smad solitary tumor cells and the graph on the right the percenta
only detected inmice injected with 4TO7-Coco cells (red bars) (H). The panels sho
all dormant 4TO7 cells and the lack of reactivity of the same antibodies with a subp
4TO7-Coco were counterstained with hematoxylin (bottom right).
(J) Control and Coco-silenced 4T1 cells were inoculated i.v. and lung sections we
P-Smad cells at the indicated times. Control cells were categorized as solitary
In all panels, error bars represent SD. See also Figure S2.matrix and might therefore accumulate at high concentrations
near the cell surface.
Interestingly, neither expression nor silencing of Coco modi-
fied the ability of tumor cells to proliferate in vitro (Figure S1H;
data not shown) or to form primary tumors when 1 3 105 cells
were injected in the mammary fat pad (Figures 1E and 1F).
Furthermore, Coco did not disrupt epithelial adhesion in normal
murine mammary epithelial cells (Figure S1I) or induce com-
pletion of an EMT program and enhance invasion in 4TO7 cells
(Figures S1J and S1K). These results suggest that Coco does
not promote primary tumor growth or invasion.
To examine if Coco promotes the colonization step of metas-
tasis, we performed tail-vein injection experiments. Expression
of Coco enabled the 4TO7 cells to metastasize efficiently to
the lung under these conditions (Figure 1G). Conversely, silenc-
ing of Coco using two distinct shRNAs suppressed the ability of
the highly metastatic 4T1 cells to colonize the lung (Figure 1H).
Similar inhibitory effects were observed upon depletion of
Coco in 66cl4 cells, which were derived from the same sponta-
neous tumor as the 4T1 cells but are less aggressive (Aslakson
and Miller, 1992) (Figure S1L; >99% inhibition), and in ErbB2-
transformedmammary tumor cells isolated fromMMTV-Neu(YD)
mice (Guo et al., 2006) (Figure S1M; >90% inhibition). We
concluded that Coco mediates lung colonization.
Coco Induces Exit from Dormancy
Confocal imaging of lung sections revealed that the 4TO7 cells
extravasate in the stroma of the lung within 1 day after injection
in the tail vein (Figures 2A and 2B). Coco did not enhance the
ability of 4TO7 cells to infiltrate the lung. However, whereas
control 4TO7 cells remained solitary and seemingly quiescent in
the stroma of this organ, a small fraction of 4TO7-Coco cells
started to proliferate from around day 14 and gave rise to meta-
static outgrowths (Figures 2A and 2B). Most of the lesions were
relatively small and had not yet undergone neoangiogenesis at
day 21 but became large and vascularized by day 35 (Figure 2A).
Although thenumberof tumorcellswithin outgrowingmicrometa-
stases was comparable to that of solitary tumor cells at day 21,
the tumorcellswithinmacrometastases far outnumbered thesoli-
tary tumor cells at day 35 (>9-fold). Anti-Ki67 staining suggested
that a large majority of solitary 4TO7 and 4TO7-Coco cells were
not actively cycling (>97%). In contrast, a large fraction of the
4TO7-Coco cells within metastatic lesions were activelyxpressing Coco were categorized as indicated. **p < 0.01.
re inoculated i.v. Lung sections were stained with anti-Ki-67 and anti-GFP. The
l cells were categorized as solitary (Sol.) or outgrowing (Out.). **p < 0.01.
ated or exposed to 1 ng/ml BMP4 for 30 min and subjected to immunoblotting
tained with anti-P-Smad 1, 5, 8, and anti-GFP. The graph on the left shows the
ge of P-Smadmetastatic outgrowths at the indicated times.Metastaseswere
w the positive staining pattern generated by anti-P-Smad antibodies on virtually
opulation of dormant 4TO7-Coco cells.Metastases arising inmice injectedwith
re stained with anti-P-Smad and anti-GFP. The graph shows the percentage of
(Sol.) or outgrowing (Out.).
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proliferating (Figures S2A and S2B). The solitary 4TO7 and 4TO7-
Coco cells were not apoptotic at any time point examined (Fig-
ure S2C), in agreementwith the hypothesis that they had become
dormant.
To confirm that the solitary tumor cells detected in the lung
were quiescent, we performed 5-ethynyl-20-deoxyuridine (EdU)
incorporation experiments (Figure 2C). Confocal imaging after
fluorescent conversion of EdU and anti-GFP staining indicated
that >95% of solitary 4TO7 and 4TO7-Coco cells did not enter
into or traverse the S-phase over each of three distinct EdU
incorporation periods. In contrast, a large fraction of 4TO7-
Coco cells within outgrowing micrometastic lesions and overt
metastases transited through the S phase over the same times
(Figures 2D and 2E). Therefore, the 4TO7 cells undergo a pro-
tracted period of solitary tumor dormancy in the lung, but ex-
pression of Coco enables a fraction of these cells to exit from
dormancy and produce metastatic outgrowths.
To examine if silencing of Coco induces dormancy, we exam-
ined the lungs of mice injected with control or Coco-silenced 4T1
cells. As anticipated, silencing of Coco did not inhibit extravasa-
tion or decrease the number of solitary tumor cells present on
lung sections at day 14 and 28 (Figure S2D). Furthermore,
whereas a fraction of control 4T1 cells initiated proliferation to
give rise to metastatic outgrowths, virtually all Coco-silenced
cells remained quiescent (Figures 2F and S2D), suggesting that
depletion of Coco suppresses lung colonization by preventing
the reactivation of dormant cells.
Coco Inhibits BMP Signaling in Metastasis-Initiating
Cells
To define the molecular underpinnings of the prometastatic
activity of Coco, we examined its ability to regulate BMP, Nodal,
and Wnt signaling in mammary tumor cells. We excluded Nodal
because the 4TO7 and 4T1 cells do not express nodal receptors
or Cripto and do not respond to Nodal in reporter assays (Figures
S2E and S2F; data not shown). However, they express two type I
and type II BMP receptors as well as Frizzled7 and LRP5 and 6
(Figures 2G and S2G). As anticipated, BMP4 induced robust
C-terminal phosphorylation of BMP-responsive Smad proteins
(1, 5, 8) in 4TO7 cells, and expression of Coco reversed this
process (Figure 2G). In contrast, Coco did not inhibit but partially
enhancedWnt signaling (Figures S2H–S2K). Cocomay exert this
latter effect by alleviating the intracellular inhibitory crosstalk that
BMP receptors exert on b-catenin (He et al., 2004; Kobielak
et al., 2007).
Immunostaining of lung sections indicated that virtually all the
solitary, dormant 4TO7 cells displayed strong nuclear accumula-
tion of P-Smad over 35 days of observation, suggesting that
BMP signaling was robustly activated in these cells (Figures 2H
and 2I). Semiquantitative RT-PCR indicated that the 4TO7 and
4T1 cells express low levels of BMP proteins, whereas the
cellular elements of the normal lung express significant levels
of several BMP proteins (Figure S2L), in general agreement
with prior data showing that both epithelial and mesenchymal
cells in the lung produce BMP (Danesh et al., 2009). Metastatic
seeding by 4TO7 or 4TO7-Coco cells did not modify the levels
of BMP mRNAs in recipient lungs (Figure S2M). We thus inferred
that the 4TO7 cells underwent protracted proliferative quies-768 Cell 150, 764–779, August 17, 2012 ª2012 Elsevier Inc.cence in response to BMP proteins that had been produced by
both epithelial and mesenchymal cells and deposited in the
stroma between alveoli.
Intriguingly, a small fraction (2%) of the dormant tumor cells
present in the lungs of mice injected with GFP-tagged 4TO7-
Coco cells displayed no nuclear accumulation of P-Smad (Fig-
ures 2H and 2I). We speculate that these cells accumulated
more Coco in their pericellular matrix or were exposed to lower
amounts of BMP as compared to other cells. In agreement
with the hypothesis that these rare P-Smad cells were fated
to produce metastatic outgrowths, both the incipient lesions
and the macrometastases displayed no nuclear accumulation
of P-Smad (Figures 2H and 2I). The solitary 4TO7 and 4TO7-
Coco cells as well as the outgrowing 4TO7-Coco cells did not
exhibit accumulation of b-catenin in the nucleus, suggesting
that b-catenin signaling does not contribute to reactivation
(Figures S2N and S2O).
In a reciprocal set of experiments, we evaluated if silencing of
Coco-induced reactivation of Smad signaling in solitary 4T1 cells
that would have been destined to give rise to metastatic lesions.
A small but sizable fraction of solitary 4T1 cells (5%) and all of
those within outgrowing metastases did not display nuclear
accumulation of P-Smad suggesting that the metastases arise
from P-Smad-negative cells (Figure 2J). This subpopulation of
P-Smad-negative cells was not detected in the lungs of mice in-
jected with Coco-silenced 4T1 cells. In fact, >99.3% of dormant
Coco-silenced 4T1 cells displayed strong nuclear accumulation
of P-Smad (Figure 2J). Together, these findings suggest that
Coco promotes exit from dormancy by alleviating the ability of
stromal BMP to enforce a dormant state.
Coco Promotes Tumor Sphere Formation In Vitro
Because the metastasis-initiating cells share functional proper-
ties with cancer stem cells (Nguyen et al., 2009; Valastyan and
Weinberg, 2011), we considered the possibility that Coco pro-
motes the manifestation of cancer stem cell traits. Phenotypic
analysis indicated that the 4TO7 and 4T1 cells express high
levels of the mammary epithelial stem cell markers CD24,
CD29, and CD49f but do not express markers found in bipoten-
tial progenitors or cells differentiated along the luminal or myoe-
pithelial lineage (Figure S3A; Table S1). In addition, both types of
cells are endowed with a program of gene expression similar to
that of normal mammary epithelial stem cells (Table S2). Tumor-
initiating cells isolated from mouse models of ErbB2-mediated
mammary tumorigenesis exhibit a similar phenotype (Lo et al.,
2011).
The cancer stem cells are defined by an inherent capability to
undergo self-renewal, to give rise to an aberrantly differentiated
progeny, and to seed tumors in vivo (Clevers, 2011; Gupta et al.,
2009). To examine if Coco affects cancer stem cell function, we
first examined its ability to influence self-renewal in vitro by using
the mammosphere assay (Dontu et al., 2003). The 4TO7-Coco
cells form about twice as many tumor spheres as compared to
4TO7 cells at each of three subsequent passages (Figures 3A
and S3B). Administration of exogenous Coco produced a similar
and dose-dependent effect in naive 4TO7 cells (Figure 3B). In
agreement with the observation that 4TO7 cells produce small
amounts of BMP2 and 5 (Figure S2L), treatment of naive 4TO7
A B C D
E F
G I
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J
Figure 3. Coco Promotes Cancer Stem Cell Traits
(A) The graph shows the number of tumor spheres at each of three subsequent passages per 103 cells seeded.
(B) Coomassie Blue staining of recombinant Coco (left) and number of tumor spheres formed by cells plated with the indicated concentrations (right).
(C andD) Cells were platedwith the indicated concentrations of Coco andBMP. The graph shows the efficiency of tumor sphere formation as compared to control
cells. ***p < 0.001 (C). Representative images (Coco: 0.9 mg/ml, BMP4: 10 ng/ml) (D).
(E and F) Outline of PKH-26 staining and serial tumor sphere assay. ErbB2-transformed cells were stainedwith PKH-26 (left) and subjected to tumor sphere assay.
The primary spheres were dissociated and their constituent cells were sorted according to staining intensity (PKHHIGH, PKHLOW, and PKHNEG) (center) and
subjected to secondary tumor sphere assays. Finally, the PKHHIGH cells from secondary tumor spheres were subjected to the same protocol to derive tertiary
tumor spheres (E). The graph show the results obtained with control and Coco-silenced ErbB2-transformed cells. *p < 0.05, **p < 0.01, ***p < 0.001. NS, not
significant.
(G and H) 4TO7 and 4TO7-Coco cells (G) and control and Coco-silenced 4T1 cells (H) were inoculated orthotopically at the indicated doses. The graphs show
mean tumor volumes.
(I and J) Q-PCR of indicated genes in 4TO7 and 4TO7-Coco cells (I) and in 4TO7 cells left untreated or exposed to 10 ng/ml BMP4 for 2 days (J).
(A–C and F) Error bars represent SD. (G–J) Error bars represent SEM. See also Figure S3 and Tables S1 and S2.
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cells with 10 ng/ml of exogenous BMP4 caused a profound inhi-
bition of tumor sphere formation, which was reversed by concur-
rent administration of Coco (Figures 3C and 3D). Neither Coco
nor BMP affected the ability of 4TO7 cells to survive or progress
through the cell cycle under the conditions of the assay (Fig-
ure S3C; data not shown). We infer that Coco expands their
ability of 4TO7 cells to give rise to tumor spheres by blocking
the small amounts of BMP that they produce.
We next evaluated if BMP can cause partial or aberrant differ-
entiation of mammary tumor cells. Notably, treatment of 4TO7
cells with BMP4 induced expression of the transcription factor
GATA3, a master regulator of luminal differentiation, whereas
concurrent administration of recombinant Coco reversed this
process (Figure S3F). In addition, whereas the 4TO7 cells that
became dormant upon extravasation in the lung stroma dis-
played strong reactivity for GATA3 irrespective of whether they
expressed Coco, the metastatic outgrowths formed by 4TO7-
Coco cells were uniformly negative for GATA3 (Figure S3G).
These results suggest that the high levels of BMP present in
the lung stroma induce the 4TO7 cells to express GATA3, and
they further imply that expression of Coco reverses this process
in tumor cells fated to give rise to metastatic outgrowths.
However, BMP4 did not induce expression of markers associ-
ated with differentiated luminal cells under standard culture
conditions or in 3D Matrigel (Table S1; data not shown). Thus,
BMP upregulates GATA3, seemingly poising breast cancer cells
toward luminal differentiation, but is insufficient to initiate partial
or aberrant differentiation en face of oncogenic signaling.
Prior studies have suggested that transgenic ErbB2mammary
tumors follow a cancer stem cell model. Staining with the lipo-
philic dye PKH-26, which is diluted after each cell division, has
indicated that the cells that retain the dye during the mammo-
sphere assay possess the highest self-renewal capacity in vitro
and the highest tumor initiation capacity in vivo (Cicalese et al.,
2009). To examine if Coco affects self-renewal in vitro, we
stained Coco-silenced and control primary tumor cells from
MMTV-Neu(YD) mice with PKH-26 and subjected them to serial
tumor sphere assay (Figure 3E). As previously reported, replating
of the PKHHIGH, PKHLOW, and PKHNEG subsets led to tumor
sphere formation in all cases, albeit with decreasing efficiency.
Notably, knock down of Coco inhibited tumor sphere formation
at each passage (Figure 3F). Treatment of naive ErbB2-trans-
formed cells with BMP4 exerted the same effect and Coco
reversed it (Figure S3D). Silencing of Coco did not reduce the
ability of ErbB2-transformed cells to survive or proliferate (Fig-
ure S3E) nor induced them to express differentiated genes in
3D Matrigel (data not shown). These results suggest that Coco
selectively sustains the ability of ErbB2-transformed cells to
undergo self-renewal in vitro.
Coco Promotes Tumor Initiation In Vivo
Prompted by the observation that Coco increases clonogenic
outgrowth under standard culture conditions as well as in soft
agar (Figures S3H and S3I), we examined if it also enhanced
tumor initiation in vivo. We found that Coco significantly in-
creases the ability of 4TO7 cells to seed tumors in vivo (Fig-
ure 3G). As anticipated, this effect was evident only when limiting
numbers of tumor cells were injected in the mammary fat pad.770 Cell 150, 764–779, August 17, 2012 ª2012 Elsevier Inc.Conversely, silencing of Coco inhibited the tumor-initiation
capacity of 4T1 cells (Figure 3H). Semiquantitative RT-PCR
experiments indicated that, although the normal cell types
present in the mammary fat pad express BMP7, the primary
tumors generated by 4TO7 or 4T1 cells injected at this site did
not express any of the BMP genes (Figure S2L). These results
suggest that Coco promotes tumor initiation in the mammary
gland as well as reactivation in the lung because it opposes
the ability of stromal BMP to block clonogenic outgrowth.
Coco Sustains Expression of Stem Cell Transcription
Factors
The transcriptional program regulated by the embryonic stem
cell transcription factors Sox2, Nanog, and Oct4 is often reacti-
vated in aggressive and metastatic breast cancers (Ben-Porath
et al., 2008; Wong et al., 2008). Furthermore, the transcriptional
coactivator Taz, which is inhibited by the Hippo tumor sup-
pressor pathway, has been recently implicated in breast cancer
stem cell maintenance (Cordenonsi et al., 2011). Q-PCR experi-
ments indicated that the 4TO7 cells express high levels of
Sox2 and lower levels of Taz and Nanog, whereas the ErbB2-
transformed cells express high levels of Oct4 and lower levels
of the remaining three transcriptional regulators (Figure S3J
and S3K). Intriguingly, Coco increased the levels of expression
of Nanog, Sox2, and Taz in 4TO7 cells (Figure 3I). Conversely,
BMP4 completely suppressed their expression (Figure 3J).
Consistently, silencing of Coco significantly reduced the level
of expression of Nanog, Oct4, and Taz and completely ablated
expression of Sox2 in ErbB2-transformed cells (Figure S3L).
Because Nanog, Sox2, and Oct4 are part of a self-sustaining
circuit that powers stem cell maintenance (Young, 2011) and
Taz appears to be specifically required in breast tumor progen-
itor cells (Cordenonsi et al., 2011), Coco may contribute to the
manifestation of breast cancer stem cell traits by influencing
the expression of these transcription factors.
Coco Promotes Metastatic Reactivation by Inhibiting
BMP Signaling
To examine the mechanism through which Coco enhances the
capability of mammary tumor cells to outgrow in the mammo-
sphere assay and during lung colonization, we transduced
4TO7 cells with Smad6, which inhibits canonical BMP signaling
(Hata et al., 1998), with the activated b-catenin mutant S4A,
or with both Smad6 and b-catenin-S4A (Figure 4A, left). These
mutant proteins exerted the anticipated signaling effects (Fig-
ures S4A–S4D). Whereas Smad6 increased tumor sphere for-
mation by approximately 2-fold, similar to Coco, activated
b-catenin did not induce this effect, either alone or with Smad6
(Figures 4A and 4B). In addition, Smad6 attenuated the induction
of GATA3 in response to BMP (Figure S4E). These results
suggest that Coco promotes self-renewal in vitro predominantly
by inhibiting BMP signaling.
To examine if inhibition of BMP signaling promotes metastatic
reactivation, we injected 4TO7 cells expressing Smad6 or acti-
vated b-catenin intravenously. Whereas Smad6 promoted lung
colonization as efficiently as Coco, activated b-catenin induced
this process to a modest extent (Figure 4C). Expression of
a dominant negative form of BMPR-IB induced both 4TO7 cells
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Figure 4. Inhibition of BMP Signaling Enhances Cancer Stem Cell Traits and Lung Colonization
(A) Cells were transduced with the indicated constructs were subjected to immunoblotting (left) and tumor sphere assay (right).
(B) Representative images.
(C) 4TO7 cells expressing the indicated constructs were inoculated i.v. The panels show representative images (top) and the graph the normalized photon flux at
the indicated times (bottom).
(D) 4T1 cells transduced as indicated were injected orthotopically at the indicated doses. The graph shows the mean tumor volumes.
(E) Cells were inoculated i.v. and lung metastasis was assessed as in (C).
In all panels, error bars represent SD. See also Figure S4.and Coco-silenced 4T1 cells to colonize the lung. However, this
construct inhibited BMP signaling and therefore promoted lung
metastasis less efficiently as compared to Smad6 (Figures
S4A, S4B, S4F, and S4G). These results indicate that inhibitionof BMP signaling rescues 4TO7 cells and Coco-silenced 4T1
cells from tumor dormancy.
As an alternative approach, we tested if BMP signaling
decreased tumor initiation. 4T1 cells coexpressing an activatedCell 150, 764–779, August 17, 2012 ª2012 Elsevier Inc. 771
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Figure 5. Coco Promotes Human Breast Cancer Metastasis
(A) Human breast cancer cells classified as indicated (Extended Experimental Procedures) were subjected to immunoblotting (Bo, bone only; L*, predominantly
lung; BaA and BaB, basal A and B; Lu, luminal).
(B) Control and Coco-silenced MDA-MB-231 cells were subjected to immunoblotting (top left) and lung colonization assay. The graph shows the normalized
photon flux (bottom left, ±SD) and the panels show representative images (right).
(C and D) Control and Coco-silenced MDA-MB-231 cells were subjected to FACS (C) and tumor sphere assay (D, left, ± SD). Viability at the end of the assay was
measured by MTT staining (D, right, ±SEM).
(E) Control and Coco-silenced MDA-MB-231 cells were inoculated orthotopically at the indicated doses in NOD/SCID/IL2Rg/ mice. The graphs show mean
tumor volumes (±SEM. *p < 0.05). **p < 0.01. n.s., not significant.
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form of BMPR-IB (Q203D) together with BMPR-II (jointly termed
CA-BMPR) were significantly less tumorigenic upon injection in
the mammary fat pad as compared to controls (Figures 4D and
S4H). These results indicate that BMP signaling suppresses
the tumor initiating capacity of 4T1 cells.
To further study the connection between tumor initiating
capacity and metastatic outgrowth, we examined the ability
of 4T1 cells expressing CA-BMPR to metastasize to the lung
upon tail vein injection. Whereas control 4T1 cells were highly
metastatic in this assay, those expressing CA-BMPR were
unable to colonize the lung, confirming that BMP signaling
opposes metastatic colonization (Figure 4E). CA-BMPR exerted
a similar effect in 4TO7-Coco cells (Figure S4I). These findings
suggest that Coco induces metastasis-initiating cells to exit
from dormancy by alleviating the capacity of lung-derived BMP
proteins to activate canonical Smad signaling.
Coco Promotes Human Breast Cancer Metastasis
To explore the role of Coco in human breast cancer metastasis,
we first examined a panel of 12 human breast cancer cell lines
(Figure 5A). Immunoblotting indicated that the nontumorigenic
or noninvasive cells as well as the ER+ cells capable of colo-
nizing the bone upon intracardiac injection exhibit low or unde-
tectable levels of Coco, whereas the MDA-MB231 cells, which
can colonize efficiently the lung and belong to the basal B
gene expression cluster associated with a stem cell phenotype,
express Coco (Figure 5A). Although, as revealed by additional
experiments, the MDA-MB231 cells express the BMP inhibitors
Noggin, DAN and Chordin-like 1 at levels comparable to those
of Coco (Figures S5A–S5C), silencing of Coco was sufficient
to suppress their ability to colonize the lung (Figures 5B
and S5B). Monitoring for 6 additional weeks revealed that the
Coco-silenced cells eventually gave rise to micrometastases
(Figure S5D, left). These lesions did not arise as a result of
re-expression of Coco but presumably through the acquisition
of genetic or epigenetic modifications able to bypass its require-
ment (Figures S5D, right, and S5E). Depletion of Coco also sup-
pressed the lung colonization ability of CN34.2a cells, which
were derived from the pleural effusion of a patient affected by
metastatic breast cancer but are not as aggressive as the
MDA-MB231 cells (Padua et al., 2008), suggesting that Coco
is a general mediator of lung colonization.
Sorting according to the surface expression of CD44 and
CD24 has been successfully used to identify cancer stem cells
within primary breast tumors or mammary cell lines, including
the MDA-MB231 cells (Al-Hajj et al., 2003; Cordenonsi et al.,
2011). As anticipated, the large majority of control MDA-
MB231 cells were CD44HIGH/CD24LOW/, consistent with a
cancer stem cell phenotype. Silencing of Coco led to the appear-
ance of a large subpopulation of cells that did not express CD44,
suggesting that expression of Coco is necessary to maintain the(F) Normal breast tissue and a case of invasive ductal carcinoma were stained wit
the positivity of nests of tumor cells and scattered stromal cells (high magnificat
(G) TMAs comprising 126 primary breast tumors were stained with anti-Coco. The
shows the distribution of staining intensity across samples.
(H) Kaplan-Meier analysis of overall survival based on Coco expression in prima
See also Figure S5 and Table S3.expression of this marker in MDA-MB231 (Figure 5C). In con-
sonance with this observation, depletion of Coco profoundly
inhibited the ability of MDA-MB231 cells to form tumor spheres
in vitro without affecting their survival or proliferation (Figures 5D,
S5G, and S5H). Finally, silencing of Coco inhibited the capacity
of MDA-MB231 cells to initiate tumorigenesis upon orthotopic
injection in NOD-SCID-IL2gR/ mice (Figure 5E). These results
provide evidence that Coco promotes maintenance of various
stem cell traits by MDA-MB231 cells.
To study the expression of Coco in human breast cancer, we
stained three distinct TMAs comprising 15 normal or dysplastic
glands and 126 breast cancers with affinity-purified antibodies
reacting selectively with Coco (Table S3; Experimental Proce-
dures). Whereas normal or dysplastic mammary epithelial cells
did not express detectable levels of Coco, the tumor cells and
scattered stromal cells in a large fraction of breast tumors
produced variable amounts of Coco (Figures 5F, 5G, and S5I).
Statistical analysis did not reveal any correlation between the
intensity of staining for Coco and pathological grade, clinical
stage, ER, or HER2 status in these samples (data not shown).
Interestingly, Kaplan-Meier analysis of the MSKCC TMA data
set, which is annotated for metastatic relapse, indicated that
the patients with primary tumors exhibiting high levels of Coco
had a significantly shorter overall survival (46.2 ± 7.7 months)
as compared to the remaining patients (104.9 ± 23.2 months)
(Figure 5H). We were not able to uncover other correlations,
possibly because of the limited number of cases present in this
TMA and the paucity of paired samples. These observations
suggest that Coco confers a selective advantage during both
tumor initiation and progression.
Coco Expression Signatures Predict Metastatic Relapse
to the Lung
DNA microarray analysis was used to examine if Coco’s activity
correlates withmetastatic relapse in human breast cancer. Many
signaling pathways, including the BMP pathway, are restrained
by negative feedback loops, which ensure expression of target
genes only after a defined threshold of signaling has been
reached. We thus reasoned that a Coco-dependent signature
of gene expression may have been more reflective of Coco’s
activity than the level of expression of CocomRNA. Furthermore,
the Affymetrix HG-U133A and Agilent platforms do not contain
probes for Coco.
DNA microarray analysis of control and Coco-silenced
MDA-MB231 cells led to the definition of a signature comprising
56 genes (Figure 6A). By using a leave-one-out cross validation
method, we identified the 14 genes most relevant in predicting
overall metastatic relapse in the NKI295 data set (Figure 6B,
left), which comprises early stage, lymphnode negative cases
(van de Vijver et al., 2002) (Table S4), and validated their predic-
tive power on the EMC286 data set (Figure S6A), whichh monospecific antibodies to Coco and counterstained with hematoxylin. Note
ion inset).
pictures show images of cases exhibiting varying levels of positivity. The graph
ry tumors.
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Figure 6. Coco Predicts Specifically Relapse to the Lung
(A) Hierarchical clustering of genes upregulated or downregulated (>2-fold) in Coco-silenced MDA-MB231 cells as compared to control cells. NDRG1 and
KIAA119 are underlined.
(B) Kaplan-Meier analysis of metastasis-free survival in the NKI295 (left) or the indicated combined data set (right). Patients were divided according to expression
of the 14-gene Coco signature (red line, positive; blue line, negative).
(C) MDA-MB231 cells and their lung and bone metastatic derivatives were subjected to immunoblotting.
(D and E) Kaplan-Meier analysis of lung-only metastasis-free survival (left), bone-only metastasis-free survival (middle), and brain-only metastasis-free
survival (right) in the MSK82, EMC192 and EMC286 combined data set. Patients were divided according to expression of the 14-gene (D) or 2-gene Coco
signature (E).
(F and G) MDA-MB-231 cells expressing a control sh-RNA (sh-Control) and two sh-RNAs targeting NDRG1 (sh-NDRG #3 and #5) (F) or two sh-RNAs targeting
KIAA1199 (sh-KIAA #1 and #5) (G) were subjected to lung colonization assay.
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comprises early stage tumors from patients, who did not
undergo adjuvant therapy after surgery (Wang et al., 2005) (Table
S4). Finally, we tested the ability of the 14-gene signature to
predict overall metastatic relapse in a combined data set
comprising the MSK82, EMC192, and EMC286 cohorts. This
large data set comprises patient populations with distinct clin-
ical, pathologic and treatment characteristics, in proportions
similar to those occurring in the breast cancer population at large
(Bos et al., 2009) (Table S4). Interestingly, the 14-gene signature
was strongly associated with overall metastatic relapse in this
cohort (p = 2.9 3 104; n = 560) (Figure 6B, right).
Further distillation of the 14-gene signature led to the identifi-
cation of two of its component genes, KIAA1199 and NDRG1,
whose combined overexpression predicted overall relapse
in the EMC286 data set with efficiency similar to that of the
14-gene signature (Figure S2B). Although both genes encode
for proteins of unknown cellular function, prior studies have sug-
gested that KIAA1199 sustains Wnt signaling in colorectal
cancer (Birkenkamp-Demtroder et al., 2011) and NDRG1 is acti-
vated by HIF-1a, through inactivation of Myc-mediated repres-
sion, and by AP-1 (Ellen et al., 2008). Interestingly, expression
of the two genes strongly correlated with poor prognosis in the
largest cohort comprising the MSK82, EMC192, EMC286, and
NKI295 data sets (p = 2.9 3 107; n = 855) (Figure S6B).
To examine if expression of Coco correlates specifically with
metastasis to the lung, we first compared the levels of Coco in
lung and bone metastatic variants of MDA-MB231 cells (Zhang
et al., 2009). Notably, Coco was upregulated in the lung meta-
static variants LM2-4180 and LM2-4175 but not in the bone
metastatic variants Bo-1833 and Bo-2287 (Figure 6C). None
of nine additional secreted BMP inhibitors had a similar pattern
of upregulation in lung metastatic variants (Figure S5A). To
corroborate the hypothesis that expression of Coco underlies
organ-specific metastasis to the lung, we evaluated if the 14-
gene and 2-gene signatures are able to selectively predict
lung metastasis. Preliminary analyses indicated that both signa-
tures were able to predict relapse to the lung but not to the
bone or brain in the MSK82, EMC192, and EMC286 data sets
(Figure S6C). To avoid the potentially confounding effect of
patients with multisite metastases, we repeated the analysis
in the large combined data set (MSK82 + EMC192 +
EMC286) after exclusion of such patients. The results indicated
that both signatures were strongly associated with lung but not
bone or brain metastasis (Figures 6D and 6E) and predicted
overall survival as well as lung metastasis independently of
transcriptomic subtype, tumor size, lymphnode positivity, ER
status, HER2 status, pathological grade, or expression of the
NKI 70-gene poor survival signature (Table S5). Finally,
although the original Coco signature comprising 56 genes dis-
played target organ-specificity similar to that of the previously
described lung metastasis signature (Figure S6D) and was
able to predict overall survival with similar efficiency (Table
S6), the two signatures only shared three genes (Table S7),(H) MDA-MB-231 cells expressing a control sh-RNA (sh-Control) or sh-RNAs tar
were subjected to lung colonization assay. The graph shows the normalized photo
bars represent SD.
See also Figure S6 and Tables S4, S5, S6, and S7.consistent with the involvement of biologically distinct mecha-
nisms (Minn et al., 2005).
To examine ifNDRG1 and KIAA1199 participated in lung colo-
nization, we silenced each of the two genes, singly or in combi-
nation, in MDA-MB231 cells (Figures S6E–S6G). Although single
silencing ofNDRG1 or KIAA1199 did not inhibit lung colonization
(Figures 6F, 6G, S6E, and S6F), simultaneous downregulation of
both genes led to a significant inhibition of lung colonization
(>80% inhibition at 10 weeks; Figures 6H and S6G), suggesting
that NDRG1 and KIAA1199 are Coco-regulated genes involved
in lung colonization.
Coco Is Not Required for Colonization of Bone or Brain
To assess if Coco participates in metastasis to the bone or brain,
we performed intracardiac injection experiments. Biolumines-
cent imaging showed that mice injected with control 4T1 cells
develop bone, brain and adrenal gland metastases (Figures 7A
and 7B). The bone lesions occurred in >80% of the mice and
were osteolytic (Figures 7A and S7A). Notably, silencing of
Coco did not reduce the rate of metastasis to bone, brain or
adrenal gland or inhibit the growth of individual lesions (Figures
7A and 7B), suggesting that Coco is not required for colonization
of these organs.
We hypothesized that Coco may mediate organ-specific
metastasis to the lung because the stroma of this organ contains
particularly high levels of bioactive BMP proteins. Because the
action of BMP proteins is regulated by multiple secreted inhibi-
tors, some of which can neutralize each other or also function
as direct activators, as well as by complex additional mecha-
nisms (Walsh et al., 2010), it is impossible to estimate the amount
of bioavailable BMP present in a given tissue by using direct
methods. Therefore, to gauge the amount of active BMP present
in the bone marrow stroma, we examined P-Smad signaling in
tumor cells that had infiltrated this microenvironment. Analysis
of bone sections from control mice indicated strong nuclear
accumulation of BMP-responsive P-Smad proteins in chondro-
cytes in the growth plate but not in most hematopoietic cells
(Figure S7B). Intriguingly, a large fraction of the solitary 4T1
cells present in the bone marrow 7 days after intracardiac
injection did not display nuclear accumulation of P-Smad (Fig-
ure 7C). Furthermore, virtually all the constituent cells in all
micrometastases and osteolytic lesions detected at 5 weeks
were similarly P-Smad-negative (Figure 7D), suggesting that
these outgrowths had originated from P-Smad-negative solitary
tumor cells. Similar results were obtained from examining the
micrometastatic lesions that arose in the bone of two out of
five mice injected with 4TO7 cells 7.5 weeks earlier (Figure 7D).
Finally, also all of the solitary tumor cells detected in the brain
parenchyma of mice injected 7 days earlier with 4T1 cells did
not display nuclear accumulation of BMP-responsive P-Smad
proteins (Figure 7C). In contrast, we had found that all the
4TO7 and more than 94% of the 4T1 cells that had undergone
dormancy in the lung were P-Smad-positive (Figures 2H andgeting NDRG1 and KIAA1199 (sh-KIAA #1/ NDRG #3 and KIAA #5/ NDRG #5)
n flux (left) and the panels show representative images (right). In all panels, error
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Figure 7. Coco-Mediated Blockage of BMP Is Not Required for Metastasis to the Bone or Brain
(A and B) Mice inoculated in left ventricle (i.c.) with control or Coco-silenced 4T1-TGL cells were subjected to bioluminescent imaging. Bone metastases were
confirmed by X-ray radiography. The panels show representative images. Yellow dotted lines delineate the boundaries of osteolytic lesions in the radiograms (A).
The graph shows the photon flux signal of metastases in the hind limbs, brains, and adrenal glands of mice (B, ±SEM).
(C) Mice were inoculated i.c. with 4T1-TGL cells and sacrificed 7 days later. Bone and brain sections were subjected to staining with anti-P-Smad and anti-GFP.
The graph shows the percentage of P-Smad+ and P-Smad tumor cells in the bone and the brain. The images show representative images.
(D) Mice were inoculated i.c. with 4T1 and 4TO7 cells and sacrificed at the indicated times. Bone sections were stained with H&E and anti-P-Smad. The graph
shows the percentage of P-Smad+ and P-Smad tumor cells in micrometastases and macrometastases generated by 4T1 cells and in micrometastatic clusters
produced by 4TO7 cells (top left). The pictures show representative images.
(E) Model of Coco’s function.
See also Figure S7.
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2J). These results suggest that the levels of bioactive BMP
proteins capable of engaging their cognate receptors on tumor
cells are low in at least a subset of stromal microenvironments
in the bone and brain. Together, these results suggest that
Coco selectively mediates colonization of the lung because it
enables tumor cells to overcome the inhibitory action of BMP
proteins that they encounter upon infiltrating this organ.
DISCUSSION
We have found that breast cancer cells that have successfully
extravasated in the lung and survived initial attrition remain
dormant for an extended period because stroma-derived BMP
proteins limit their ability to proliferate. Production of Coco
enables a fraction of these cells to overcome inhibitory BMP
signaling and to outgrow into macrometastases. Thus, although
most disseminated tumor cells may possess intrinsic defects
that preclude them from surviving or undergoing active pro-
liferation in the lung, those that are fated to give rise to clinical
metastases, themetastasis-initiating cells, face strong antimeta-
static signals originating from the parenchyma of this organ
(Figure 7E).
It is plausible that only a subpopulation of tumor cells—the so
called cancer stem cells—possess the extensive self-renewal
capability necessary for successful colonization of target organs
(Clevers, 2011; Valastyan and Weinberg, 2011). Our results
suggest that BMP enforces tumor dormancy by repressing two
key cancer stem cell traits: self-renewal in vitro and tumor initia-
tion in vivo. They further suggest that Coco induces exit from
dormancy by reversing the ability of BMP to inhibit cancer
stem cell function. This model is consistent with previous studies
indicating that the BMP pathway inhibits self-renewal and pro-
motes differentiation in pluripotent stem cells and various adult
stem cells (Varga and Wrana, 2005). In addition, it is in general
agreement with the observation that BMP signaling contributes
to inhibit mesenchymal and stem cell states in human mammary
epithelial cells (Scheel et al., 2011).
Of interest, BMP profoundly inhibited the expression of the
transcription factors Nanog, Sox-2, and Oct-4, which comprise
the core regulatory circuit that sustains embryonic stem cells
(Young, 2011), and of the Hippo transducer Taz, which confers
stem cell-related traits on breast cancer cells (Cordenonsi
et al., 2011). In contrast, Coco enhanced the expression of these
transcriptional regulators by reversing the effect of BMP. We
presume that the interrelationships between these transcrip-
tional regulators are complex, and that each component con-
tributes to sustain a cancer stem cell program of gene ex-
pression, underlying the functions necessary for metastatic
reactivation. In fact, the transcriptional modules that include as
core components Nanog, Sox-2, and Oct-4 as well as Taz/Yap
are overexpressed in aggressive and metastatic solid tumors
(Ben-Porath et al., 2008; Wong et al., 2008).
The observation that Coco promotes colonization of the lung,
but not of the bone or brain, reveals the existence of organ-
specific barriers to metastatic reactivation. A large fraction of
breast cancer cells that infiltrated the bone marrow stroma and
virtually all of those that lodged in the brain parenchyma to
give rise to metastatic outgrowths did not display nuclear accu-mulation of BMP-responsive P-Smads, suggesting that they
had not been exposed to high levels of bioactive BMP. Thus,
although they may face additional barriers, many tumor cells
that infiltrate the bone or the brain do not need to neutralize
locally produced BMP in order to outgrow. Because pretreat-
ment with BMP blocks the ability of MDA-MB231 cells to colo-
nize the bone after intracardiac injection (Buijs et al., 2011), we
speculate that breast cancer cells that infiltrate the bone are
sensitive to the inhibitory action of BMP. They simply do not
need to avert it through production of Coco because they lodge
within sanctuaries devoid of the cytokine.
Several lines of evidence indicate that Coco is a particularly
potent mediator of metastatic reactivation and that it exerts its
effect by inhibiting lung-derived BMP (Extended Discussion). In
particular, Coco was the only BMP inhibitor whose expression
correlated with lung metastatic capacity. Furthermore, although
the MDA-MB231 cells expressed Chordin-like 1, DAN, and
Noggin at levels similar to those of Coco, knock down of Coco
was sufficient to block the lung metastatic capacity of these
cells. Although all secreted BMP inhibitors function as ligand
traps, some have additional functions. Furthermore, individual
members differ in oligomerization state, affinity for individual
BMP proteins, and ability to bind to the extracellular matrix
(Walsh et al., 2010). Therefore, Coco might be a particularly
potent mediator of lung colonization because it has a very high
affinity for BMP proteins or because it binds to the pericellular
matrix and therefore reaches a very high concentration near
the cell surface. However, we cannot exclude the possibility
that Coco induces metastatic reactivation in the lung also
through BMP-independent mechanisms, which remain to be
defined.
The lag phase that separates the entry of tumor cells
producing Coco into the lung stroma and their outgrowth sug-
gests that additional adaptive mechanisms mediate lung
colonization. Signals initiated by b1 integrins enable the initial
outgrowth of tumor cells that have established productive inter-
actions with the interstitial matrix of this organ (Shibue and
Weinberg, 2009). In addition, the matrix proteins Tenascin C
and Periostin organize niches that nurse outgrowing micrometa-
stases by modulating Notch and Wnt signaling, respectively
(Malanchi et al., 2012; Oskarsson et al., 2011). Although these
signaling mechanisms have not been specifically linked to the
reactivation of solitary tumor cells, it is possible that they coop-
erate with Coco to drive this process. Alternatively, they may act
following initial outgrowth to foster the expansion of micrometa-
static lesions, similar to the role of VCAM-1 in osteolytic bone
lesions (Lu et al., 2011). Our observation that activated b-catenin
does not mediate exit from solitary tumor cell dormancy is
consistent with the hypothesis that Periostin falls in this latter
class of prometastatic entities.
Attesting to the clinical relevance of our findings, patients with
breast carcinomas expressing high levels of Coco exhibited
reduced overall survival. Furthermore, expression of a 14-gene
Coco signature predicted relapse to the lung but not to the
bone or brain, in agreement with the notion that Coco specifically
promotes colonization of the lung. Provocatively, further distilla-
tion of the signature led to the identification of two genes that
maintained an intact ability to predict relapse to the lung and,Cell 150, 764–779, August 17, 2012 ª2012 Elsevier Inc. 777
in fact, participated in this process in a mouse model. Based on
these observations, we suggest that the 14-gene and 2-gene
signatures may be used to identify patients with a significant
risk to develop lung metastases. Furthermore, we propose that
monoclonal antibodies or other biological agents blocking
Coco may exhibit antimetastatic activity.
Coco has emerged from a gain-of-function retroviral
cDNA screen in a mouse model of lung metastatic dormancy.
The identification of Coco demonstrates that such screens
could be used to define the genes that mediate the exit of
solitary tumor cells from dormancy in the lung. Furthermore,
similar screens using genome-wide shRNA libraries might
enable the identification of genes that promote dormancy.
Finally, both cDNA and shRNA screens could be applied to other
mouse models to identify the mechanisms that regulate tumor
dormancy at other metastatic sites or to investigate other steps
of the metastatic cascade. By affording the advantage of rapid
biological validation of single entities that are able to enforce
dormancy or mediate exit from it, such gain-of-function genetic
screens should lead to the identification of additional potential
therapeutic targets for the treatment of metastatic disease.
EXPERIMENTAL PROCEDURES
Retroviral cDNA Screen
Size-fractionated retroviral cDNA libraries were constructed essentially as
described previously (Koh et al., 2004). 67NR, 168FARN, or 4TO7 cells were
infected independently with the libraries at a multiplicity of infection (MOI) of
3:1 and injected in the mammary fat pad of BALB/c mice. Clonogenic tumor
cells isolated from macrometastases were expanded in selective medium
(Aslakson and Miller, 1992). Proviral DNA was rescued and sequenced as
described previously (Koh et al., 2002).
Animal Studies
Tumorigenesis and metastasis assays were performed as previously
described (Pylayeva et al., 2009). Animal studies were conducted in accor-
dance with protocols approved by the Institutional Animal Care and Use
Committee of MSKCC.
Tumor Sphere Assays
Mammosphere assays were performed essentially as previously described
(Dontu et al., 2003). ErbB2 cells were stained with PKH-26 dye and sub-
jected to sequential tumor sphere assays as described earlier (Cicalese
et al., 2009).
Human Metastasis Samples
TMAs containing primary breast tumors and lung metastases were generated
by the MSKCC Department of Pathology in compliance with protocols
approved by the MSKCC Institutional Review Board and after the subjects
gave their informed consent. Coco immunoreactivity was evaluated and
scored by a clinical pathologist (E.B.). Overall survival was examined as a func-
tion of Coco abundance in breast tumor samples.
Statistical Analysis
Comparisons between two groups were performed using an unpaired two-
sided t test (p < 0.05 was considered significant). Results are reported as
mean ± SD or ± SEM unless otherwise noted. All in vitro experiments were per-
formed at least three times.
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